<- Go home

Added to YB: 2025-11-11

Pitch date: 2025-11-07

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

+37.43%

current return

Author Info

Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 13.92

Price Target

N/A

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

growth

Show full summary:
Cipher Pharmaceuticals Q3 2025 Update

CPH.TO (earnings): Q3 rev $12.8M (+24% YoY), Natroba $8.1M (+47%), adj EBITDA $7.3M (+79%). Debt down to $8M from $45M, expect debt-free by YE. Trading 10x EV/FCF, 9.3x EV/EBITDA. DTC launch 2026, Canada filing Q4. Multiple growth catalysts but market wants M&A details.

Read full article (3 min)